Compare Amphastar Pharmaceuticals Inc (AMPH) vs Roblox Corp (RBLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Roblox Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Roblox Corp trades at $55.5 (market cap $39.63B). The key difference: Roblox Corp is far larger — about 48× Amphastar Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| AMPH | RBLX | |
|---|---|---|
Market Cap | $826.08M | $39.63B |
Sector | Health | Media |
52-Week High | $30.81 | $141.56 |
52-Week Low | $16.87 | $41.30 |
Enterprise Value | $1.22B | $38.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Roblox (RBLX) trades at $55.35, down 1.9% on the day, amid a bullish technical signal and strong analyst support. The stock shows consistent revenue growth, with 2025 revenue reaching $4.89 billion, though it remains unprofitable with a net income margin of -20.69%. Recent earnings have beaten expectations, but the company faces headwinds from a securities class action lawsuit related to age-verification disclosures. Operating cash flow improved to $1.8 billion in 2025, signaling healthy core business operations despite ongoing losses.
The outlook for RBLX is mixed; robust user monetization and revenue growth present upside potential, supported by a consensus price target of $64.07. However, persistent losses, high valuation multiples like a P/B of 91.73, and legal risks weigh on investor confidence. The stock's trajectory hinges on achieving profitability and navigating regulatory scrutiny, making it a high-risk, growth-oriented play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →
